Lee's Pharmaceutical Holdings Ltd. (950) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Lee's Pharmaceutical Holdings Ltd.

Dawnrays Pharmaceutical Holdings Ltd.

TOT BIOPHARM International Co. Ltd.

Shanghai Henlius Biotech, Inc.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Charmacy Pharmaceutical Co., Ltd.

Antengene Corp. Ltd.

Clover Biopharmaceuticals Ltd.

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd.

Transcenta Holding Ltd.

Fusen Pharmaceutical Co., Ltd.

Why is Lee's Pharmaceutical Holdings Ltd. ?

High Management Efficiency with a high ROE of 16.32%

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 74.18

Positive results in Dec 24

PRE-TAX PROFIT(Q) At HKD 37.6 MM has Grown at 833.82%
NET PROFIT(Q) At HKD 30.62 MM has Grown at 5,170.4%
ROCE(HY) Highest at 5.04%

With ROE of 14.79%, it has a Very Attractive valuation with a 0.65 Price to Book Value

Over the past year, while the stock has generated a return of 36.29%, its profits have risen by 6.8% ; the PEG ratio of the company is 0.7
At the current price, the company has a high dividend yield of 248.6

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Lee's Pharmaceutical Holdings Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Lee's Pharmaceutical Holdings Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Lee's Pharmaceutical Holdings Ltd.

21.58%

0.61

63.07%

Hang Seng Hong Kong

27.36%

1.03

25.88%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

13.55%

EBIT Growth (5y)

13.25%

EBIT to Interest (avg)

74.18

Debt to EBITDA (avg)

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

0.44

Tax Ratio

21.23%

Dividend Payout Ratio

28.46%

Pledged Shares

Institutional Holding

0.03%

ROCE (avg)

26.07%

ROE (avg)

16.32%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.65

EV to EBIT

4.71

EV to EBITDA

4.43

EV to Capital Employed

0.65

EV to Sales

1.06

PEG Ratio

0.66

Dividend Yield

248.62%

ROCE (Latest)

13.72%

ROE (Latest)

14.79%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is working for Lee's Pharmaceutical Holdings Ltd.

Pre-Tax Profit

At HKD 37.6 MM has Grown at 833.82%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (HKD MM)

Net Profit

At HKD 30.62 MM has Grown at 5,170.4%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (HKD MM)

Net Sales

Highest at HKD 741.62 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (HKD MM)

Net Sales

At HKD 741.62 MM has Grown at 37.15%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (HKD MM)

Inventory Turnover Ratio

Highest at 2.21%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Depreciation

At HKD 77.28 MM has Grown at 9.69%

period on period (QoQ)

MOJO Watch

The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (HKD MM)

Here's what is not working for Lee's Pharmaceutical Holdings Ltd.

Operating Cash Flow

Lowest at HKD 355.8 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (HKD MM)

Interest

Highest at HKD 7.4 MM

in the last five periods and Increased by 9.08% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (HKD MM)

Raw Material Cost

Grown by 9.87% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales